Tech Company Financing Transactions
Tricida Funding Round
On 11/9/2017, Tricida announced $57.5 million in Series D investment from Cormorant Asset Management, Limulus Venture Partners and Longitude Capital Management.
Transaction Overview
Company Name
Announced On
11/9/2017
Transaction Type
Venture Equity
Amount
$57,500,000
Round
Series D
Investors
Proceeds Purpose
Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101, Tricida's first-in-class investigational drug candidate for the treatment of chronic metabolic acidosis in patients with chronic kidney disease (CKD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Ct. 201
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Tricida, Inc. is an innovative startup company focused on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerrit Klaerner
Chief Financial Officer
Geoffrey Parker
Chief Technical Officer
Wilhelm Stahl
Vice President
Dawn Parsell
VP - Bus. Development
Claire Lockey
VP - General Counsel
Edward Hejlek
Browse more venture capital transactions:
Prev: 11/9/2017: Leanplum venture capital transaction
Next: 11/9/2017: Modern Adventure venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs